Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1066

1.

Monitoring diffuse injury during disease progression in experimental autoimmune encephalomyelitis with on resonance variable delay multiple pulse (onVDMP) CEST MRI.

Thomas AM, Xu J, Calabresi PA, van Zijl PCM, Bulte JWM.

Neuroimage. 2019 Oct 9:116245. doi: 10.1016/j.neuroimage.2019.116245. [Epub ahead of print]

PMID:
31605825
2.

NLRX1 inhibits the early stages of CNS inflammation and prevents the onset of spontaneous autoimmunity.

Gharagozloo M, Mahmoud S, Simard C, Yamamoto K, Bobbala D, Ilangumaran S, Smith MD, Lamontagne A, Jarjoura S, Denault JB, Blais V, Gendron L, Vilariño-Güell C, Sadovnick AD, Ting JP, Calabresi PA, Amrani A, Gris D.

PLoS Biol. 2019 Sep 16;17(9):e3000451. doi: 10.1371/journal.pbio.3000451. eCollection 2019 Sep.

3.

Corticostriatal synaptic plasticity alterations in the R6/1 transgenic mouse model of Huntington's disease.

Ghiglieri V, Campanelli F, Marino G, Natale G, Picconi B, Calabresi P.

J Neurosci Res. 2019 Sep 9. doi: 10.1002/jnr.24521. [Epub ahead of print]

PMID:
31498496
4.

Quetiapine has an additive effect to triiodothyronine in inducing differentiation of oligodendrocyte precursor cells through induction of cholesterol biosynthesis.

Gonzalez Cardona J, Smith MD, Wang J, Kirby L, Schott JT, Davidson T, Karnell JL, Whartenby KA, Calabresi PA.

PLoS One. 2019 Sep 6;14(9):e0221747. doi: 10.1371/journal.pone.0221747. eCollection 2019.

5.

Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinson's disease.

Krashia P, Cordella A, Nobili A, La Barbera L, Federici M, Leuti A, Campanelli F, Natale G, Marino G, Calabrese V, Vedele F, Ghiglieri V, Picconi B, Di Lazzaro G, Schirinzi T, Sancesario G, Casadei N, Riess O, Bernardini S, Pisani A, Calabresi P, Viscomi MT, Serhan CN, Chiurchiù V, D'Amelio M, Mercuri NB.

Nat Commun. 2019 Sep 2;10(1):3945. doi: 10.1038/s41467-019-11928-w.

6.

Current and emerging evidence-based treatment options in chronic migraine: a narrative review.

Agostoni EC, Barbanti P, Calabresi P, Colombo B, Cortelli P, Frediani F, Geppetti P, Grazzi L, Leone M, Martelletti P, Pini LA, Prudenzano MP, Sarchielli P, Tedeschi G, Russo A; Italian chronic migraine group.

J Headache Pain. 2019 Aug 30;20(1):92. doi: 10.1186/s10194-019-1038-4. Review.

7.

Oligodendrocyte precursor cells present antigen and are cytotoxic targets in inflammatory demyelination.

Kirby L, Jin J, Cardona JG, Smith MD, Martin KA, Wang J, Strasburger H, Herbst L, Alexis M, Karnell J, Davidson T, Dutta R, Goverman J, Bergles D, Calabresi PA.

Nat Commun. 2019 Aug 29;10(1):3887. doi: 10.1038/s41467-019-11638-3.

8.

Glutamine antagonism attenuates physical and cognitive deficits in a model of MS.

Hollinger KR, Smith MD, Kirby LA, Prchalova E, Alt J, Rais R, Calabresi PA, Slusher BS.

Neurol Neuroimmunol Neuroinflamm. 2019 Aug 29;6(6). pii: e609. doi: 10.1212/NXI.0000000000000609. Print 2019 Nov.

9.

Dystonia and levodopa-induced dyskinesias in Parkinson's disease: Is there a connection?

Calabresi P, Standaert DG.

Neurobiol Dis. 2019 Aug 22;132:104579. doi: 10.1016/j.nbd.2019.104579. [Epub ahead of print] Review.

PMID:
31445160
10.

Cerebrospinal fluid neurofilament light chain predicts disease activity after the first demyelinating event suggestive of multiple sclerosis.

Gaetani L, Eusebi P, Mancini A, Gentili L, Borrelli A, Parnetti L, Calabresi P, Sarchielli P, Blennow K, Zetterberg H, Di Filippo M.

Mult Scler Relat Disord. 2019 Jul 27;35:228-232. doi: 10.1016/j.msard.2019.07.025. [Epub ahead of print]

PMID:
31404762
11.

The genetic diversity of multiple sclerosis risk among Hispanic and African American populations living in the United States.

Beecham AH, Amezcua L, Chinea A, Manrique CP, Rubi C, Isobe N, Lund BT, Santaniello A, Beecham GW, Burchard EG, Comabella M, Patsopoulos N, Fitzgerald K, Calabresi PA, De Jager P, Conti DV, Delgado SR, Oksenberg JR, McCauley JL.

Mult Scler. 2019 Aug 1:1352458519863764. doi: 10.1177/1352458519863764. [Epub ahead of print]

PMID:
31368393
12.

Glial pathology and retinal neurotoxicity in the anterior visual pathway in experimental autoimmune encephalomyelitis.

Jin J, Smith MD, Kersbergen CJ, Kam TI, Viswanathan M, Martin K, Dawson TM, Dawson VL, Zack DJ, Whartenby K, Calabresi PA.

Acta Neuropathol Commun. 2019 Jul 31;7(1):125. doi: 10.1186/s40478-019-0767-6.

13.

Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning.

Sotirchos ES, Filippatou A, Fitzgerald KC, Salama S, Pardo S, Wang J, Ogbuokiri E, Cowley NJ, Pellegrini N, Murphy OC, Mealy MA, Prince JL, Levy M, Calabresi PA, Saidha S.

Mult Scler. 2019 Jul 31:1352458519864928. doi: 10.1177/1352458519864928. [Epub ahead of print]

PMID:
31364464
14.

DeepHarmony: A deep learning approach to contrast harmonization across scanner changes.

Dewey BE, Zhao C, Reinhold JC, Carass A, Fitzgerald KC, Sotirchos ES, Saidha S, Oh J, Pham DL, Calabresi PA, van Zijl PCM, Prince JL.

Magn Reson Imaging. 2019 Jul 10. pii: S0730-725X(18)30649-0. doi: 10.1016/j.mri.2019.05.041. [Epub ahead of print]

PMID:
31301354
15.

Early complement genes are associated with visual system degeneration in multiple sclerosis.

Fitzgerald KC, Kim K, Smith MD, Aston SA, Fioravante N, Rothman AM, Krieger S, Cofield SS, Kimbrough DJ, Bhargava P, Saidha S, Whartenby KA, Green AJ, Mowry EM, Cutter GR, Lublin FD, Baranzini SE, De Jager PL, Calabresi PA.

Brain. 2019 Sep 1;142(9):2722-2736. doi: 10.1093/brain/awz188.

PMID:
31289819
16.

Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial.

Cadavid D, Mellion M, Hupperts R, Edwards KR, Calabresi PA, Drulović J, Giovannoni G, Hartung HP, Arnold DL, Fisher E, Rudick R, Mi S, Chai Y, Li J, Zhang Y, Cheng W, Xu L, Zhu B, Green SM, Chang I, Deykin A, Sheikh SI; SYNERGY study investigators.

Lancet Neurol. 2019 Sep;18(9):845-856. doi: 10.1016/S1474-4422(19)30137-1. Epub 2019 Jul 5.

PMID:
31285147
17.

Long-Term Risk of Stroke After Transient Global Amnesia in Two Prospective Cohorts.

Romoli M, Tuna MA, McGurgan I, Li L, Giannandrea D, Eusebi P, Tordo Caprioli F, Lotti A, Salvadori N, Sarchielli P, Gili A, Mosconi MG, Pellizzaro Venti M, Stracci F, Ricci S, Paciaroni M, Parnetti L, Calabresi P, Rothwell PM.

Stroke. 2019 Sep;50(9):2555-2557. doi: 10.1161/STROKEAHA.119.025720. Epub 2019 Jul 9.

PMID:
31284848
18.

Applications of a deep learning method for anti-aliasing and super-resolution in MRI.

Zhao C, Shao M, Carass A, Li H, Dewey BE, Ellingsen LM, Woo J, Guttman MA, Blitz AM, Stone M, Calabresi PA, Halperin H, Prince JL.

Magn Reson Imaging. 2019 Jun 24. pii: S0730-725X(18)30650-7. doi: 10.1016/j.mri.2019.05.038. [Epub ahead of print]

PMID:
31247254
19.

The levels of the NMDA receptor co-agonist D-serine are reduced in the substantia nigra of MPTP-lesioned macaques and in the cerebrospinal fluid of Parkinson's disease patients.

Nuzzo T, Punzo D, Devoto P, Rosini E, Paciotti S, Sacchi S, Li Q, Thiolat ML, Véga C, Carella M, Carta M, Gardoni F, Calabresi P, Pollegioni L, Bezard E, Parnetti L, Errico F, Usiello A.

Sci Rep. 2019 Jun 20;9(1):8898. doi: 10.1038/s41598-019-45419-1.

20.

The Italian version of Cognitive Function Instrument (CFI) for tracking changes in healthy elderly: results at 1-year follow-up.

Chipi E, Montanucci C, Eusebi P, D'Andrea K, Biscetti L, Calabresi P, Parnetti L.

Neurol Sci. 2019 Oct;40(10):2147-2153. doi: 10.1007/s10072-019-03960-x. Epub 2019 Jun 12.

PMID:
31190254
21.

Synaptic vesicle protein 2A tumoral expression predicts levetiracetam adverse events.

Romoli M, Mandarano M, Romozzi M, Eusebi P, Bedetti C, Nardi Cesarini E, Verzina A, Calvello C, Loreti E, Sidoni A, Giovenali P, Calabresi P, Costa C.

J Neurol. 2019 Sep;266(9):2273-2276. doi: 10.1007/s00415-019-09410-0. Epub 2019 Jun 5.

PMID:
31168673
22.

Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis.

Gaetani L, Salvadori N, Lisetti V, Eusebi P, Mancini A, Gentili L, Borrelli A, Portaccio E, Sarchielli P, Blennow K, Zetterberg H, Parnetti L, Calabresi P, Di Filippo M.

J Neurol. 2019 Sep;266(9):2157-2163. doi: 10.1007/s00415-019-09398-7. Epub 2019 May 25.

PMID:
31129709
23.

T2*-weighted MRI values correlate with motor and cognitive dysfunction in Parkinson's disease.

Tambasco N, Paolini Paoletti F, Chiappiniello A, Lisetti V, Nigro P, Eusebi P, Chiarini P, Romoli M, Brahimi E, Simoni S, Filidei M, Floridi P, Tarducci R, Parnetti L, Calabresi P.

Neurobiol Aging. 2019 Aug;80:91-98. doi: 10.1016/j.neurobiolaging.2019.04.005. Epub 2019 Apr 11.

PMID:
31103636
24.

Alterations in the retinal vasculature occur in multiple sclerosis and exhibit novel correlations with disability and visual function measures.

Murphy OC, Kwakyi O, Iftikhar M, Zafar S, Lambe J, Pellegrini N, Sotirchos ES, Gonzalez-Caldito N, Ogbuokiri E, Filippatou A, Risher H, Cowley N, Feldman S, Fioravante N, Frohman EM, Frohman TC, Balcer LJ, Prince JL, Channa R, Calabresi PA, Saidha S.

Mult Scler. 2019 May 16:1352458519845116. doi: 10.1177/1352458519845116. [Epub ahead of print]

PMID:
31094280
25.

Substantia nigra hyperechogenicity in essential tremor and Parkinson's disease: a longitudinal study.

Cardaioli G, Ripandelli F, Paolini Paoletti F, Nigro P, Simoni S, Brahimi E, Romoli M, Filidei M, Eusebi P, Calabresi P, Tambasco N.

Eur J Neurol. 2019 Nov;26(11):1370-1376. doi: 10.1111/ene.13988. Epub 2019 Jun 27.

PMID:
31094036
26.

Longitudinal assessment of hand function in individuals with multiple sclerosis.

Newsome SD, von Geldern G, Shou H, Baynes M, Marasigan RER, Calabresi PA, Zackowski KM.

Mult Scler Relat Disord. 2019 Jul;32:107-113. doi: 10.1016/j.msard.2019.04.035. Epub 2019 May 6.

PMID:
31085489
27.

Validation of the Hemifacial Spasm Grading Scale: a clinical tool for hemifacial spasm.

Tambasco N, Simoni S, Sacchini E, Eusebi P, Marsili E, Nigro P, Brahimi E, Paoletti FP, Romoli M, Calabresi P.

Neurol Sci. 2019 Sep;40(9):1887-1892. doi: 10.1007/s10072-019-03921-4. Epub 2019 May 10.

PMID:
31076941
28.

Quantal Release of Dopamine and Action Potential Firing Detected in Midbrain Neurons by Multifunctional Diamond-Based Microarrays.

Tomagra G, Picollo F, Battiato A, Picconi B, De Marchis S, Pasquarelli A, Olivero P, Marcantoni A, Calabresi P, Carbone E, Carabelli V.

Front Neurosci. 2019 Apr 9;13:288. doi: 10.3389/fnins.2019.00288. eCollection 2019.

29.

Dopamine drives binge-like consumption of a palatable food in experimental Parkinsonism.

Mineo D, Cacace F, Mancini M, Vannelli A, Campanelli F, Natale G, Marino G, Cardinale A, Calabresi P, Picconi B, Ghiglieri V.

Mov Disord. 2019 Jun;34(6):821-831. doi: 10.1002/mds.27683. Epub 2019 Apr 19.

PMID:
31002748
30.

CSF and blood biomarkers for Parkinson's disease.

Parnetti L, Gaetani L, Eusebi P, Paciotti S, Hansson O, El-Agnaf O, Mollenhauer B, Blennow K, Calabresi P.

Lancet Neurol. 2019 Jun;18(6):573-586. doi: 10.1016/S1474-4422(19)30024-9. Epub 2019 Apr 10. Review.

PMID:
30981640
31.

Neurofilament light chain as a biomarker in neurological disorders.

Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H.

J Neurol Neurosurg Psychiatry. 2019 Aug;90(8):870-881. doi: 10.1136/jnnp-2018-320106. Epub 2019 Apr 9. Review.

PMID:
30967444
32.

Incidence and prevalence of Parkinson's disease in the Italian region of Umbria: a population-based study using healthcare administrative databases.

Eusebi P, Franchini D, De Giorgi M, Abraha I, Montedori A, Casucci P, Calabresi P, Tambasco N.

Neurol Sci. 2019 Aug;40(8):1709-1712. doi: 10.1007/s10072-019-03872-w. Epub 2019 Apr 3.

PMID:
30945089
33.

Alpha-synuclein targets GluN2A NMDA receptor subunit causing striatal synaptic dysfunction and visuospatial memory alteration.

Durante V, de Iure A, Loffredo V, Vaikath N, De Risi M, Paciotti S, Quiroga-Varela A, Chiasserini D, Mellone M, Mazzocchetti P, Calabrese V, Campanelli F, Mechelli A, Di Filippo M, Ghiglieri V, Picconi B, El-Agnaf OM, De Leonibus E, Gardoni F, Tozzi A, Calabresi P.

Brain. 2019 May 1;142(5):1365-1385. doi: 10.1093/brain/awz065.

34.

Differential effect of FHM2 mutation on synaptic plasticity in distinct hippocampal regions.

Iure A, Mazzocchetti P, Bastioli G, Picconi B, Costa C, Marchionni I, Casari G, Tozzi A, Pietrobon D, Calabresi P.

Cephalalgia. 2019 Sep;39(10):1333-1338. doi: 10.1177/0333102419839967. Epub 2019 Mar 28.

PMID:
30922082
35.

Macular Ganglion Cell and Inner Plexiform Layer Thickness Is More Strongly Associated With Visual Function in Multiple Sclerosis Than Bruch Membrane Opening-Minimum Rim Width or Peripapillary Retinal Nerve Fiber Layer Thicknesses.

Nguyen J, Rothman A, Gonzalez N, Avornu A, Ogbuokiri E, Balcer LJ, Galetta SL, Frohman EM, Frohman T, Crainiceanu C, Calabresi PA, Saidha S.

J Neuroophthalmol. 2019 Mar 26. doi: 10.1097/WNO.0000000000000768. [Epub ahead of print]

PMID:
30921169
36.

Quantitative vibratory sensation measurement is related to sensory cortical thickness in MS.

Fritz NE, Eloyan A, Glaister J, Dewey BE, Al-Louzi O, Costello MG, Chen M, Prince JL, Calabresi PA, Zackowski KM.

Ann Clin Transl Neurol. 2019 Feb 19;6(3):586-595. doi: 10.1002/acn3.734. eCollection 2019 Mar.

37.

A nurse-led model increases quality of care in Parkinson disease.

Calabresi P, Nigro P, Schwarz HB.

Neurology. 2019 Apr 16;92(16):739-740. doi: 10.1212/WNL.0000000000007295. Epub 2019 Mar 22. No abstract available.

PMID:
30902906
38.

Layer boundary evolution method for macular OCT layer segmentation.

Liu Y, Carass A, He Y, Antony BJ, Filippatou A, Saidha S, Solomon SD, Calabresi PA, Prince JL.

Biomed Opt Express. 2019 Feb 4;10(3):1064-1080. doi: 10.1364/BOE.10.001064. eCollection 2019 Mar 1.

39.

Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: An international study.

Nolan-Kenney RC, Liu M, Akhand O, Calabresi PA, Paul F, Petzold A, Balk L, Brandt AU, Martínez-Lapiscina EH, Saidha S, Villoslada P, Al-Hassan AA, Behbehani R, Frohman EM, Frohman T, Havla J, Hemmer B, Jiang H, Knier B, Korn T, Leocani L, Papadopoulou A, Pisa M, Zimmermann H, Galetta SL, Balcer LJ; International Multiple Sclerosis Visual System Consortium.

Ann Neurol. 2019 May;85(5):618-629. doi: 10.1002/ana.25462. Epub 2019 Apr 10.

PMID:
30851125
40.

Retinal measurements predict 10-year disability in multiple sclerosis.

Rothman A, Murphy OC, Fitzgerald KC, Button J, Gordon-Lipkin E, Ratchford JN, Newsome SD, Mowry EM, Sotirchos ES, Syc-Mazurek SB, Nguyen J, Caldito NG, Balcer LJ, Frohman EM, Frohman TC, Reich DS, Crainiceanu C, Saidha S, Calabresi PA.

Ann Clin Transl Neurol. 2019 Jan 19;6(2):222-232. doi: 10.1002/acn3.674. eCollection 2019 Feb.

41.

Imaging outcome measures of neuroprotection and repair in MS: A consensus statement from NAIMS.

Oh J, Ontaneda D, Azevedo C, Klawiter EC, Absinta M, Arnold DL, Bakshi R, Calabresi PA, Crainiceanu C, Dewey B, Freeman L, Gauthier S, Henry R, Inglese M, Kolind S, Li DKB, Mainero C, Menon RS, Nair G, Narayanan S, Nelson F, Pelletier D, Rauscher A, Rooney W, Sati P, Schwartz D, Shinohara RT, Tagge I, Traboulsee A, Wang Y, Yoo Y, Yousry T, Zhang Y, Sicotte NL, Reich DS; North American Imaging in Multiple Sclerosis Cooperative.

Neurology. 2019 Mar 12;92(11):519-533. doi: 10.1212/WNL.0000000000007099. Epub 2019 Feb 20. Review. Erratum in: Neurology. 2019 Jul 2;93(1):46.

PMID:
30787160
42.

The Madwoman: a portrait of a choreic woman?

Cupini LM, Calabresi P.

Lancet Neurol. 2019 Mar;18(3):233. doi: 10.1016/S1474-4422(18)30502-7. Epub 2019 Feb 12. No abstract available.

PMID:
30784552
43.

Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancement.

Bhargava P, Wicken C, Smith MD, Strowd RE, Cortese I, Reich DS, Calabresi PA, Mowry EM.

Mult Scler Relat Disord. 2019 May;30:136-140. doi: 10.1016/j.msard.2019.02.013. Epub 2019 Feb 11.

PMID:
30771580
44.

Striatal spreading depolarization: Possible implication in levodopa-induced dyskinetic-like behavior.

de Iure A, Napolitano F, Beck G, Quiroga Varela A, Durante V, Sciaccaluga M, Mazzocchetti P, Megaro A, Tantucci M, Cardinale A, Punzo D, Mancini A, Costa C, Ghiglieri V, Tozzi A, Picconi B, Papa SM, Usiello A, Calabresi P.

Mov Disord. 2019 Jun;34(6):832-844. doi: 10.1002/mds.27632. Epub 2019 Feb 13.

PMID:
30759320
45.

Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis.

Sotirchos ES, Gonzalez-Caldito N, Dewey BE, Fitzgerald KC, Glaister J, Filippatou A, Ogbuokiri E, Feldman S, Kwakyi O, Risher H, Crainiceanu C, Pham DL, Van Zijl PC, Mowry EM, Reich DS, Prince JL, Calabresi PA, Saidha S.

Mult Scler. 2019 Feb 11:1352458519826364. doi: 10.1177/1352458519826364. [Epub ahead of print]

PMID:
30741108
46.

Selective inhibition of mitochondrial sodium-calcium exchanger protects striatal neurons from α-synuclein plus rotenone induced toxicity.

Bastioli G, Piccirillo S, Castaldo P, Magi S, Tozzi A, Amoroso S, Calabresi P.

Cell Death Dis. 2019 Jan 28;10(2):80. doi: 10.1038/s41419-018-1290-6.

47.

Retinal layer parcellation of optical coherence tomography images: Data resource for multiple sclerosis and healthy controls.

He Y, Carass A, Solomon SD, Saidha S, Calabresi PA, Prince JL.

Data Brief. 2018 Dec 28;22:601-604. doi: 10.1016/j.dib.2018.12.073. eCollection 2019 Feb.

48.

Dimethyl fumarate treatment induces lipid metabolism alterations that are linked to immunological changes.

Bhargava P, Fitzgerald KC, Venkata SLV, Smith MD, Kornberg MD, Mowry EM, Haughey NJ, Calabresi PA.

Ann Clin Transl Neurol. 2018 Oct 30;6(1):33-45. doi: 10.1002/acn3.676. eCollection 2019 Jan.

49.

Multisite reliability and repeatability of an advanced brain MRI protocol.

Schwartz DL, Tagge I, Powers K, Ahn S, Bakshi R, Calabresi PA, Todd Constable R, Grinstead J, Henry RG, Nair G, Papinutto N, Pelletier D, Shinohara R, Oh J, Reich DS, Sicotte NL, Rooney WD; NAIMS Cooperative.

J Magn Reson Imaging. 2019 Sep;50(3):878-888. doi: 10.1002/jmri.26652. Epub 2019 Jan 16.

PMID:
30652391
50.

PET imaging of microglia by targeting macrophage colony-stimulating factor 1 receptor (CSF1R).

Horti AG, Naik R, Foss CA, Minn I, Misheneva V, Du Y, Wang Y, Mathews WB, Wu Y, Hall A, LaCourse C, Ahn HH, Nam H, Lesniak WG, Valentine H, Pletnikova O, Troncoso JC, Smith MD, Calabresi PA, Savonenko AV, Dannals RF, Pletnikov MV, Pomper MG.

Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1686-1691. doi: 10.1073/pnas.1812155116. Epub 2019 Jan 11.

Supplemental Content

Loading ...
Support Center